Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
Agendia’s Microarray-based Gene Expression Profile Provides Critical Additional Information for Treatment Decisions for Stage II Colon Cancer Patients IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 1, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint Read More